Kane Biotech Inc.
KNE.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 4.10M | 3.52M | -3.84M | -3.69M | -3.12M |
| Total Depreciation and Amortization | 154.90K | 165.50K | 170.20K | 174.90K | 172.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -7.75M | -7.35M | 884.20K | 722.20K | 1.18M |
| Change in Net Operating Assets | -621.10K | -586.70K | 401.40K | 432.10K | 518.20K |
| Cash from Operations | -4.11M | -4.25M | -2.38M | -2.36M | -1.25M |
| Capital Expenditure | -19.70K | -18.10K | -10.60K | -6.80K | -1.80K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 6.99M | 6.99M | -- | -- | -- |
| Other Investing Activities | -385.30K | -405.20K | -73.20K | -78.50K | -81.20K |
| Cash from Investing | 6.59M | 6.57M | -83.70K | -85.20K | -82.90K |
| Total Debt Issued | 0.00 | 1.00M | 1.00M | 2.01M | 2.01M |
| Total Debt Repaid | -6.65M | -6.65M | -649.90K | -482.30K | -354.80K |
| Issuance of Common Stock | 232.50K | 399.10K | 399.10K | 399.10K | 415.30K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 809.70K | 785.60K | 2.19M | 1.06M | 204.00K |
| Cash from Financing | -4.11M | -3.25M | 2.15M | 2.19M | 1.61M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.63M | -936.30K | -313.00K | -260.80K | 272.60K |
